SynthesisMolecular psychiatry2026
Efficacy and safety of esketamine on major depression, postpartum depression and perioperative depression: a systematic review and meta-analysis.
Synthesis in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Effects of opioid-free anesthesia on postoperative anxiety in patients undergoing modified radical mastectomy for breast cancer: a randomized controlled trial.BMC anesthesiology · 2026Trial
- Esketamine hydrochloride in the management of moderate-to-severe depressive symptoms in patients undergoing multiple wound repair surgeries: A multi-centre randomized, double-blind, placebo-controlled trial.Clinical and translational medicine · 2026Trial
- Peripheral Nerve Blocks Modulate the Pain-Mood Relationship in Bariatric Surgery: A Secondary Analysis of a Randomized, Controlled Trial.Drug design, development and therapy · 2026Trial
- Intraoperative esketamine for postoperative analgesia and depression in pancreatic cancer surgery: protocol for a multicenter randomized controlled trial.Annals of medicine · 2026Article
- A crucial cautionary note on frequently incorrect dose equivalence between ketamine and esketamine.Molecular psychiatry · 2026Article
- The Relationship Between Trace Elements and Depression.Nutrients · 2026Review
- Esketamine for Postoperative Depressive Symptoms: Considerations for Broader Perioperative Practice [Response to Letter].Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This review and meta-analysis aimed to evaluate esketamine in managing major depressive disorder (MDD) / treatment resistant depression (TRD), preventing postpartum depression (PPD) and postoperative depression, including comparisons within and between administrations. Five databases (Pubmed, MEDLINE, Embase, Web of science and the Cochrane Library) were searched up to July 24, 2025. Randomized clinical trials investigating esketamine for depression, compared with control group were included. Efficacy outcomes included depression scales, remission rate, response rate and depression incidence rates. Safety outcomes included adverse events reported in more than two comparisons. Standardized mean differences (SMDs) and Relative risks (RRs) with their corresponding 95% confidential intervals (CIs) were estimated using fixed- or random-effects models. Administration regimes were ranked using surface under the cumulative ranking. Of 12,285 studies identified, 67 trials with 11,553 participants were included: 19 trials on MDD/TRD, 18 studies on PPD and 30 studies on postoperative depression. The overall pooled SMDs, compared with comparator, showed effective in treating and preventing depression (MDD -0.36, 95%CI -0.49, -0.24; PPD for postpartum 6 week -0.40, 95%CI -0.78, -0.02, and postoperative depression for postoperative 3 month -0.82, 95%CI -1.46, -0.18). Intravenous administration yields the greatest effect in treating MDD/TRD and preventing PPD, no matter of the measured outcome (scales scores, response rate of MDD/TRD or incidence rate of PPD or postoperative depression). Esketamine was associated with higher incidences of dizziness in both therapeutic and preventive effects. These findings highlight both short- and long-term efficacy of eskatemine in treating MDD/TRD, and preventing PPD and postoperative depression, with efficacy differing across administration routes.
Indexed as
Identifiers
41152407What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.